10x Genomics, Inc. (TXG) stock
Close on Nov 11, 2026Market cap $8.08BP/E –Yield –
10x Genomics, Inc. saw revenue fall 3.6% to $618.58M over the twelve months to Sep 30, 2026. Free cash flow was $93.77M, up 14.8% from a year earlier. At the latest close the market valued the company at $8.08B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $8.08B
- P/E ratio
- –
- Price to sales
- 13.07
- Price to book
- 9.65
- Dividend yield
- –
- Free cash flow yield
- 1.16%
Fundamentals
- Revenue
- $618.58M
- Net income
- -$67.08M
- EPS, diluted
- -$0.52
- Free cash flow
- $93.77M
- Book value per share
- $6.41
- Diluted shares
- 131M
Trading
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Previous close
- $62.90
- Open
- $66.50
- Day's range
- $61.98 – $68.94
- Volume
- 1,754,944
- Average volume (20 days)
- 3,326,331
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 2.08
- 52-week range
- $15.12 – $102.81
- RSI (14 days)
- 42.3
- Volatility (1 year)
- 76.0%
- Relative volume
- 0.53×
- WACC
- 15.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TXG | S&P 500 | Difference | TXG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.1% | -2.4% | −20.7 pts | ||
| 3 months | +6.1% | -1.2% | +7.3 pts | ||
| Year to date | +280.4% | +12.3% | +268.1 pts | ||
| 1 year | +274.0% | +12.4% | +261.6 pts | ||
| 3 years | +74.9% | +78.8% | −3.9 pts | +20.5% | +21.4% |
| 5 years | -63.0% | +75.2% | −138.2 pts | -18.1% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases 10x Genomics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About 10x Genomics
Laboratory Analytical Instruments
10x Genomics, Inc. is a life sciences technology company that develops integrated solutions to interrogate and analyze biological systems. Its product portfolio spans instruments, consumables, and software across single-cell analysis and spatial biology platforms. The single-cell offering, anchored by the Chromium system, partitions samples into barcoded components for high-throughput multiomic readouts. The spatial biology portfolio features the Visium and Xenium platforms, which enable tissue-scale spatial transcriptomics and in situ optical imaging of gene expression without conventional sequencing. A complementary software ecosystem, including pipeline and visualization tools, supports experimental planning, data processing, and analysis. The company primarily serves academic, government, biotechnology, and biopharmaceutical research institutions.
Company profile, executives and history10x Genomics stock: common questions
What is 10x Genomics's stock price?
TXG closed at $62.05 on Nov 11, 2026, down 1.35% on the day. Over the past 52 weeks it traded between $15.12 and $102.81.
What is 10x Genomics's market cap?
10x Genomics was worth $8.08B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TXG's P/E ratio?
10x Genomics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.52), so it has no meaningful P/E ratio.
How much revenue does 10x Genomics make?
10x Genomics reported revenue of $618.58M for the twelve months to Sep 30, 2026, down 3.6% from a year earlier.
Does 10x Genomics pay a dividend?
No. 10x Genomics has not paid a cash dividend over the last twelve months.
When does 10x Genomics report earnings next?
10x Genomics is expected to report Q4 FY2026 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TXG stock performed over the past year?
Including dividends, TXG returned +274.0% over the past year, against +12.4% for the S&P 500.
How many TXG shares are sold short?
12M shares were sold short at the latest FINRA report, 10.00% of the float, or 4.1 days of average trading volume.
Who are 10x Genomics's competitors?
Companies most similar to 10x Genomics by business, industry and size include PACB, CTKB, QTRX, ILMN, RVTY.
See a number that looks wrong?